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Complement protein C1q, the recognition molecule of the classical pathway, performs
a diverse range of complement and non-complement functions. It can bind various
ligands derived from self, non-self, and altered self and modulate the functions of immune
and non-immune cells including dendritic cells and microglia. C1q involvement in the
clearance of apoptotic cells and subsequent B cell tolerance is more established now.
Recent evidence appears to suggest that C1q plays an important role in pregnancy
where its deficiency and dysregulation can have adverse effects, leading to preeclampsia,
missed abortion, miscarriage or spontaneous loss, and various infections. C1q is also
produced locally in the central nervous system, and has a protective role against
pathogens and possible inflammatory functions while interacting with aggregated proteins
leading to neurodegenerative diseases. C1q role in synaptic pruning, and thus CNS
development, its anti-cancer effects as an immune surveillance molecule, and possibly in
aging are currently areas of extensive research.
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Introduction
C1q, the first recognition subcomponent of the complement classical pathway, is a 460 kDa hexam-
eric glycoprotein (1–3), which is composed of 18 polypeptide chains, composed of 9 non-covalently
linked subunits having 6 of A (223 residues; 34 kDa), B (226 residues; 32 kDa), and C (217 residues;
27 kDa) chains (Figure 1). These chains have a short N-terminal region (3–9 residues), a collagen
region having 81 residues and a C-terminal globular (gC1q) domain of about 185 residues (3, 4).
The hexameric C1q molecule has a tulip-like structure made up of structural units, which combine
in the fibril-like central portion (5). Crystal structure of the heterotrimeric gC1q domain, solved at
1.9 Å resolution, revealed an almost spherical (diameter of 50Å), dense hetrotrimer associated by
non-polar forces with Ca2+ ion bound at the top, showing a classical jellyroll topology (6). A strong
structural homology with gC1q domain [mouse ACRP30, human collagen X, mouse collagen VIII
Abbreviations: CERT, ceramide transporter protein; CJD, Creutzfeldt–Jakob disease; CNS, central nervous system; CRP, C-
reactive protein; DAF, decay-accelerating factor; DC, dendritic cells; dsDNA, double-stranded DNA; FDC, follicular dendritic
cells; GABA, gamma-aminobutyric acid; HIV, human immunodeficiency virus; IL-6, interleukin-6; HTLV-1, human T-
lymphotropic virus 1; LAIR, leukocyte-associated Ig-like receptor; LPS, lipopolysaccharides; MAC,membrane attack complex;
MCP, membrane co-factor protein; NGF, nerve growth factor; pDC, plasmacytoid dendritic cell; PrP, prion protein; PrPSc,
scrapie-associated prion protein; PS, phosphatidylserine; RGC, retinal ganglionic cells; ROS, reactive oxygen species; SLE,
systemic lupus erythematosus; TNF-α, tumor necrosis factor-alpha; TGF-β, transforming growth factor-beta.
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FIGURE 1 | Structure of C1q. The hexameric C1q molecule (460 kDa) has
a tulip-like structure, composed of nine non-covalently linked subunits of six
A, B, and C chains; A–B dimer is 52,750Da and C–C dimer is 47,600Da.
Fragments of C1q after pepsin digestion at pH 4.4 contain six intact
connecting strands and small non-collagen-like peptides. After partial
proteolysis with collagenase at pH 7.4, the globular regions (gC1q) appear
intact. C1q binds to Fc regions of IgG or IgM, HIV-1, phosphatidylserine,
HTLV-1, C-reactive protein, damaged neurons, myelin debris, amyloid fibrils,
and apoptotic cells via the gC1q domain. The collagen-like region binds to
serine proteases such as C1r and C1s leading to activation of the classical
pathway. Collagen region of C1q also binds to C1q receptors (most notably,
cC1qR or calreticulin using CD91 as a cell-surface adaptor) to augment
phagocytosis by phagocytic cells and mount a pro-inflammatory immune
response.
(α1) and human C1q] has given rise to a C1q family with a
β sandwich jellyroll topology similar to tumor necrosis factor
(TNF), and hence, a C1q–TNF superfamily (7, 8).
C1q is a pattern recognition molecule as it has the ability to
identify various structures and ligands on microbial surfaces,
apoptotic cells, or indirectly via antibodies and C-reactive protein
(CRP). C1q can bind IgG, IgM, HIV-1, phosphatidylserine (PS),
HTLV-1, CRP, and many other ligands via gC1q domain, and also
to various receptors including calreticulin-CD91, and integrin
α2β1 (4, 9). Binding of C1q to most of its ligands is via gC1q
domain, which involves recognition of charged patterns/clusters
(7). Recently, a number of functions of C1q have been described
that do not involve classical pathway activation, suggesting
that C1q has an additional role to play in homeostasis and
development.
Modulation of Dendritic Cells Maturation
and Functions by C1q
Dendritic cells (DCs) are antigen capturing and presenting cells
of innate immunity (10, 11). Interstitial/dermal DCs (IDDCs)
produce significantly more C1q at 48 h, following stimulation
with IL-4 and granulocyte macrophage-colony stimulating factor
(GM-CSF), as compared to Langerhans cells (12, 13). C1q has
been shown to be produced by renal DCs in a mouse model
of progressive lupus nephritis. Renal sections of mice showed
significantly higher expression of C1q in tubulo-interstitium of
oldMRL/lprmice as compared to youngMRL/lprmice. Increased
co-localization of MHC-II+ cells with C1q was detected in old
MRL/lprmice (5months) with lupus nephritis. Production of C1q
derived from bone marrow precursors showed expression of C1q
similar to other local sources such as macrophages. Furthermore,
human kidney biopsies of systemic lupus erythematosus (SLE)
patients showed an increased production of C1q by renal
DCs (10).
C1q binds monocyte-derived immature DCs causing the NF-
κB nuclear translocation from the cytoplasm. C1q enhances mat-
uration of DC exhibiting raised surface expression of CD83,
CD86, HLA-DR, and CCR7. Both gC1q and collagen region can
independently induce DC maturation. In the presence of C1q,
DCs secretemore IL-12p70 than immatureDCs (14). C1q-primed
mature DCs induce production of IFN-γ by co-cultured T lym-
phocytes (Th1 cells), stimulated by IL-12, and secreted by C1q-
treated mature DCs (14). C1q produced by DCs is capable of
activating complement and binding to apoptotic cells. C1q pro-
duction by DCs is suppressed by IFN-α (15). Interestingly, C1q
inhibits IFN-α production by plasmocytoid DCs (pDCs) induced
by immune complexes (ICs), but enhances IFN-α production
induced by herpes simplex virus (16).
Leukocyte-associated Ig-like receptor (LAIR; a transmembrane
protein and a member of immunoglobulin super family) (17)
is expressed on NK cells, B cells, monocytes, human fetal thy-
mocytes, and T cells. LAIR 1 is an inhibitory receptor, which is
considered to be involved in down-regulation of immune response
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(17). C1q binding to LAIR leads to the activation of LAIR-1
signaling. C1q inhibits the GM-CSF and IL-4 stimulated differen-
tiation of monocytes into DCs. Interaction of C1q with LAIR-2
reduces the expression of LAIR-1 and CD14, implying that the
C1q-mediated differentiation of DCs is reversed by LAIR-2 (18).
C1q and LAIR-1 also function to inhibit IFN-α production by
plasmacytoid DCs of either healthy or SLE individuals. This sug-
gests that C1q and LAIR-1 interaction is involved in the arrest of
monocyte differentiating to DCs, and in the inhibition of plasma-
cytoid DC activation (18). Furthermore, C1q expression by DCs
can be localized at the arterial wall. Atherosclerotic lesions showed
intracellular and extracellular expression of C1q, particularly the
necrotic core surroundings were C1q-positive. C1q expression
was not only limited to DCs but also to other cell types such as
macrophages, neovascular endothelial cells within atherosclerotic
plaques, endothelium of vasa vasorum in the adventitia, and in
very few luminal endothelial cells. The expression of DCs in
the arterial lesions was heterogeneous, implying that some DCs
may reside in the arterial wall for local synthesis of C1q (19).
Consistent with this, C1q binding to apoptotic cells enhances the
phagocytosis and stimulates the production of IL-6, IL-10, and
TNF-α by DCs, without affecting IL-12p70 production.
C1q binds to resting as well as activated B cells. C1q may
be involved in the stimulation of B cells to either produce
IgM or IgG isotypes in normal individuals or those with
impaired B cell activity (20). Studies on C1q deficient( / ) mice
have demonstrated that positive selection of B cells and IgM
autoantibodies is increased by intracellular self-antigens that are
displayed by dying cells, and the negative selection of B cells is
decreased. The positive selection by self-antigens may be involved
in the IgM and C1q-dependent clearance of dying cells, limiting
the contact of conventional B cells to immunogenic self-antigens
(21). C1q deficient mice developed splenic hypercellularity,
displaying signs of accelerated CD4+ T cell activation, enhanced
splenic plasma cells and total serum IgM levels. This suggests
splenic monocytosis is caused by C1q deficiency as well as the
activation of T cells in an autoimmune-prone mouse strain
(22). C1q deficient mice also develop lupus-like disease and the
apoptotic cells have elevated levels of autoantigens as these are
not cleared by complement. Mice genetically deficient in C1q
displayed high levels of IgM and IgG3 (23).
Clearance of Apoptotic Cells by C1q and
Its Role in Immune Tolerance
Waste Disposal and Self-Tolerance Hypotheses
Apoptosis plays an integral part in development and homeostasis,
through tissue and organ remodeling and in homeostatic cell
turnover (24–26). C1q is important in development, and has
a major role in clearing apoptotic cells, which may otherwise
encourage autoimmunity. C1q deficiency predisposes one with a
high risk to develop SLE, a prototype of autoimmune inflamma-
tory disease (27). Twomain hypotheses onC1q related autoimmu-
nity have been proposed, being apparently complementary. In the
first “waste disposal hypothesis,” due to C1q deficiency in clearing
apoptotic bodies, an accumulated bulk of altered self apoptotic
neo-antigens may induce in lymphatic tissues an uncontrolled
affinity maturation and IgG isotype switching of specific self-
reactive B cell clones in a T cell dependent manner (27). Accord-
ing to the second “self-tolerance hypothesis,” C1q and C4 also
maintain peripheral tolerance-anergy of naturally occurring IgM
producing self-reactive B cell clones against specific apoptotic
antigens such as histone and dsDNA as part of apoptotic cell
homeostasis. Some of these clones may be eliminated through
their negative selection centrally in bone marrow and spleen (28).
Nuclear antigens are highly conserved and may cross-react with
bacteria. Their autoimmunity is typical of SLE (29, 30).
Apoptosis is an evolutionarily preserved death program medi-
ated by caspase proteases and regulated by pro-apoptotic and anti-
apoptotic signals of adjacent cells (24). Affected cells undergo
characteristic cell shrinkage, non-random nuclear protein and
DNA fragmentation, plasma membrane blebbing, and exposure
of PS on their membrane surface. Blebs-apoptotic bodies are rich
in nuclear material including dsDNA targeted by autoantibodies
in SLE (24). PS is an important early apoptotic molecule recog-
nized by C1q (in addition to other target ligands as shown in
Table 1) and by other phagocytic cell receptors, such as CD36 and
TIM-4. It enables a rapid cell phagocytosis before their release of
inflammatory molecules (31, 32).
SLE is strongly associated with C1q and C4 deficiency. Hered-
itary C1q deficiency, which is very rare, confers in homozygous
persons at an early age, a more than 90% risk of developing the
disease (27, 56). Deficiency in C4 carries a disease risk of around
80%. However, SLE is a heterogeneous complex disease due to
acquired C1q deficiency, although there may be remissions (57).
Symptoms, which are very variable, include skin rash, light sen-
sitivity, glomerulonephritis, and arterial-venous thrombosis. SLE
is mediated by autoantibodies to various self-antigens, predomi-
nantly to C1q and apoptotic blebs containing nuclear antigens. Its
hallmark is deposition of ICs with such antigens (58). Immuno-
logical changes can precede the disease, sometimes several years
in advance (28).
C1q, C4, and C3 proteins are involved in specific antigen pre-
sentation by DCs to T and B cells. DCs are central in processing
self and non-self-antigens during immune response (59). In a
physiological steady state, tissue immature migrating DCs sam-
ple microbe and tissue antigens, and in draining lymph nodes
differentiate into follicular DCs, where they mature and present
processed specific antigens to naive T cells in a MHC-dependent
manner. Such antigen specific Th cells, in turn, interact via their
receptorwith antigen specific B cell, whichmay require T cell help.
FDCs can also directly present antigens to specific immature B
cells in lymphoid cell compartment (29, 60). However, in most
cases, for efficient antigen B cell receptor (BCR) activation, self
or microbial antigens are covalently tagged with adjuvants C3d or
C3dg fragments as opsonins (61).
Possible Involvement of C1q Receptors in
Tolerance
Of a number of candidate C1q receptors, two receptors for C1q,
cC1qR and gC1qR, have been largely documented in the lit-
erature. cC1qR (now known as calreticulin) was identified on
phagocytic cell surface as a receptor for the collagen region of
C1q (and collectins) (62). Another C1q receptor specific to the
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TABLE 1 | Emerging non-complement functions of C1q.
C1q functions Mechanisms Ligands/receptors Reference
Canonical Wnt signaling, induces aging C1s-dependent cleavage of the
ectodomain of LRP6
Frizzled receptors (Fz) (33)
LRP5/6
Invasion of epithelial and endothelial cells C1q collagen region with the host
cell-surface receptor interaction
S. pneumoniae serotype 35A (NCTC10319),
S. pneumoniae strain D39 (serotype 2)
(34)
Clearance of bacterial pathogens Gram-positive (S. pyogenes) and
Gram-negative (E. coli)
Collagen region; outer membrane protein from
Gram  ve bacteria
(34–36)
Lipopolysaccaride, fibronectin, fibrin, fibrinogen
Escape mechanism for Streptococcus pneumoniae C1q and PepO interaction Pneumococcal endopeptidase O (PepO) (37)
Induction of apoptosis in cells overexpressing WOX1 Phosphorylation of N-terminal WW
domain of WOX1
WOX1 (38)
Induction of angiogenesis Vessel formation during wound
healing
gC1q domain (39)
Clearance of apoptotic cells gC1q domain PS (40–44)
dsDNA
Calreticulin
Annexin A2 and A5
Tolerance induction Immature DCs C1q/gC1qR (45, 46)
cC1qR
Developmental synaptic pruning Microglia (47)
Uptake and transmission of PrPSc from the gut to the brain Conventional DCs Calreticulin (49, 50)
Forms complexes of PrP oligomers gC1q domain (51)
Development of DC DC gC1qR (52)
Induction of tolerance phenotype cC1qR (53)
Tolerogenic effect (TGF-β1 release)
Negatively influences BCR signaling; enhances tolerance B cell (54)
Induces anti-inflammatory response B cells (55)
Inhibits activation and proliferation T cell gC1qR (54)
globular head region, gC1qR, has also been described (63). Like
C1q, the two receptors also seem to have multiple specificity and
functions. C1q receptors are C1q collagen-like domain binding
calreticulin (cC1qR), and C1q globular domain binding protein
receptor (gC1qR) p33 (63). Calreticulin is part of multi-protein-
binding scavenger receptor complex CD91, of which β chain is
a transmembrane signaling protein. C1q/cC1qR/CD91 complex
bound apoptotic cells can be taken up by immature DCs through
their micropinocytosis (42, 43). Curiously, CD91 can also directly
bind C1q (65). gC1qR is also an ubiquitous co-receptor with
multi-ligand interaction and effector properties in various tissues.
For example, in immature DCs, it interacts with transmembrane
DC-SIGN-1 lectin receptor (66).
C1q, through two of its receptors (cC1qR and gC1qR), is
involved differentially in monocyte–DC development (52). C1q
may thus be involved in modulation of a specific antigen-
associated phenotype of DCs, such as tolerance/anergy in the case
of apoptotic nuclear antigens (63). Upon these antigen stimula-
tions, mature DC subsets express immunosuppressive cytokines
dominated by TGF-β and IL-10 (67), which may impact on
specific self-reactive B cell clone development (30). Moreover,
tissue migrating DC subsets, in contrast to resident follicular DC
derived from blood, have the capacity to transformCD4+ Th cells
into peripheral CD4+ CD25+ FoxP3 T-regulatory cells (Tregs),
specific for an antigen. For example, myelin specific Tregs strongly
ameliorated experimental autoimmune encephalomyelitis (EAE)
(68). A subpopulation of monocytes migrating from various tis-
sues to lymph nodes, express only minimally DC markers, while
ingesting antigens (69). Such DC apoptotic and other antigen spe-
cific tolerogenic bias are apparently impaired in C1q deficiency,
which may result in autoimmunity.
C1q, as a molecular pattern sensor, can directly bind PS as
well as to nuclear antigens including dsDNA exposed on apop-
totic blebs/bodies of various tissue cells such as keratinocytes and
vascular endothelial cells. These complexes may be rapidly taken
up through its C1q receptors by non- and professional phagocytes
such as immature DCs andmacrophages (40, 70). This feature has
been studied with UV-B irradiated early apoptotic HeLa cells. C1q
strongly interacted via multiple regions of its gC1q domain with
PS on apoptotic cells (41). Calreticulin binds to gC1q, as well as
to C1q collagen-like domain (cC1q) (71, 72). gC1q domain also
possesses a lectin-like region in recognizing late apoptotic bodies
DNA, i.e., its deoxy--ribose form (73).
cC1qR and gC1qR contribute to the development of DCs,
during which they become differentially expressed, and conse-
quently to naïve T-cell antigen presentation and to antigen specific
T cell–B cell interaction (52). Normally, a steady state relation
between both C1q receptors may be maintained, which may be
perturbed in C1q deficiency. DCs are major extrahepatic produc-
ers of C1 complex, which can become expressed on their surface,
acting in a paracrine way. This may include facilitating antigen
presentation to naïve T cells (74). Such anchored C1q might on
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contact with apoptotic cell, help to induce in DCs a tolerogenic
phenotype. As studied with macrophages, an initial close contact
with apoptotic cells, possibly by tethering receptors, is needed for
these tolerogenic effects, including TGF-β1 release. This cell state
appears to be independent of receptors, whichmediate PS exposed
apoptotic cell phagocytosis such as CD36 and αvβ5 integrin, as
tested with mice deficient in these genes (53).
TIM and Tolerogenic Phenotypes
A PS-specific apoptotic cell phagocyte receptor, TIM4 (T-cell
immunoglobulin- and mucin-domain-containing molecule) has
been cloned from mice peritoneal macrophages (31, 32). Instead
of apoptotic cells, PS coated nuclei ejected from erythroid precur-
sors were used in hemophagocytosis tests. A recent study found
TIM4 requirement for β1 integrin interaction for apoptotic cell
engulfment (75). A striking property of apoptotic cells is an impos-
ing induction in immune cells such as monocytes–macrophages
and certain DC subsets of a tolerogenic–anergic cytokine pheno-
type includingTGF-β1, IL-10, andPGE2 (42, 67, 71, 76).However,
for DC maturation and antigen presentation, a preceding pro-
inflammatory phase, possibly to apoptotic antigens, is required.
TIM3 ligand galectin-9 was shown to mediate human DC mat-
uration by inducing IL-12 and TNF-α cytokines through NF-κB
activation, in synergizing with TLRs (77). By contrast, in Th cells,
TIM-3 can have an inhibitory effect on Th1 inflammatory phe-
notype, as well as on macrophages where it down-regulates IL-12
production. TIM-3 ameliorates murine EAE (78, 79). In inflam-
matory conditions, such as viral infection,monocyte-derivedDCs
assume an IL-10 suppressive phenotype through PS dependent
hemophagocytosis to relief inflammation (80). Recently, a key
Treg subset has been described in mice, expressing C-type lectin
receptor CD69 and FoxP3+CD69+, regulated by STAT5 and ERK
pathway (81). CD69 is involved in maintenance of tolerance, in
regulation of pro- and anti-inflammatory Th17–Th2 cell pheno-
types, and in expression of TGF-β1. Patients with an active SLE
were found to be deficient in CD4+CD25high Treg cell suppressive
function (82).
Besides the effects on DCs, C1q was previously shown to
directly inhibit T cell activation and proliferation via its gC1qR
expressed on these cells (54). This receptor is also expressed on
B-cells, where it may have tolerogenic effect (83). It has been
suggested that this C1q/gC1qR negative regulatory pathway may
be involved in maintenance of peripheral self-tolerance to nuclear
antigens (46, 63). TIM-3 takes part in apoptotic cell recognition
and uptake byDC, in antigen cross-presentation to T cells, in ame-
lioration of autoimmune disease, and in immune cell tolerance
induction. TIM-3, together with TIM-4, suppressed autoantibody
production (79, 84). TIM-3 negative effects on Th1 appear to
be similar to that of C1q/gC1qR showing anergy of T cells (54).
TIM-3 is also associated, gC1qR dependently, with regulation
of suppressor of cytokine signaling-1 protein (SOCS-1) and of
opposing STAT-1 (83, 85).
Clearance by C1q of apoptotic bodies is regarded to be an
important protective function, since its impairment is associated
with renal, vascular, and other tissue deposition of complement
components and of apoptotic bodies. If not rapidly removed, the
altered self-debris may become immunogenic, exposing cryptic
epitopes, leading to induction of autoantibody production (27, 56,
86, 87). Paradoxically, SLE, despite C1q deficiency, is a comple-
ment activation inflammatory disorder. Perhaps, MBL-associated
serine proteases (MASPs) coupled with classical pathway may
substitute for C1q inflammatory function (43). Alternative path-
way may also become involved (86). C1q would thus appear pro-
tective against the disease through its putative tolerogenic effects
(30, 46). As shown with macrophages, apoptotic cell clearance
receptors are separate from the ones mediating tolerance (53).
Further supporting this view is the finding in mice deficient in
mannose binding lectin (MBL), and in CD14 receptors. Such
animals exhibited apoptotic cell and debris deposition in vari-
ous organs, but did not develop a SLE-like autoimmune pathol-
ogy (74, 88, 89).
According to self-tolerance hypothesis, C1q and C4 may
through immature DCs and immature B cell responses maintain
a threshold for negative selection of antigen specific self-reactive
B cells (30). In SLE, the main immune targets are highly con-
served ribonucleoproteins. Natural IgMproducing B cells, specific
against these proteins, are kept anergic by C1q, C4, and by Tregs.
Inert B cells may escape their apoptosis when unduly activated in
the absence of C1q or C4 (29, 30). Using a mouse model of SLE
associated with C4 deficiency, it has been revealed that tolerance
and anergy of self-reactive B cell clones are impaired, which is nor-
mally maintained through interaction with bone marrowmyeloid
cells, and by spleen negative clonal selection. In the absence of C4,
more of such antigen specific B cells reach maturity in peripheral
lymphoid compartment, effects furthered by accumulated nuclear
debris (90). Perhaps, by appearing so influential in self-tolerance,
C1q and C4might function in epistasis, i.e., being interdependent
in their cell signaling.
Self-tolerogenic C1q/gC1qR pathway could potentially endow
C1q with a protective function, distinct from that of C1q in
apoptotic debris removal (30, 46, 63). These two C1q proper-
ties in immature DCs seem to vary in their receptors they may
engage, i.e., C1q/gC1qR and C1q/cC1qR, respectively (42, 46,
64). In addition to self-reactive B cell clone elimination, their
peripheral suppression by Tregs may be diminished as seen in
patients with diseases such as SLE and anti-phospholipid syn-
drome (APS) (82, 91).
In a physiological steady state, immature DCs of various tis-
sues sample apoptotic cell and other debris in order to migrate
to lymphatic tissue where they, as follicular DC, may undergo
maturation and immune activation by either presenting specific
antigens via MHC class II to naïve T cells, or be tolerized (59). A
role of C1q in self-tolerance, as well as in apoptotic cell removal,
would be consistent with murine SLE model, rendered deficient
in their C1q A-chain gene as homozygotes (C1q / ). Such mice
had shortened life span, a quarter developing glomerulonephritis
with apoptotic body deposits, and ICs with autoantibodies (92).
C1q, Autoimmunity, and B Cell Tolerance
B cells are major effectors in SLE autoimmunity. Fate of immature
B cell stages to maturity is selected via their antigen IgM/IgG
membrane receptor (BCR) signaling, and modulated by several
positive and opposing co-factors receptor, including T cell help
(60, 93, 94). In these events, membrane bound complement
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receptor 2 (CR2, CD21), as part of BCR complex, include the sig-
naling co-receptor CD19. CD21 captures C3d/microbe or altered
self-antigen complexes, for antigenic-specific BCR stimulation. At
the same time, C3d/antigen ligated CD21 activates CD19, which
amplifies antigen specific BCR signaling, synergistically with BCR
(95). Antigen-sensitivity of BCR complex is further boosted by
co-receptor CD21–C3d/Ag complex, which cross-links a number
of BCR complexes on a B cell membrane by being polyvalent,
e.g., in ratio 3-C3d/1-Ag. Such structures can lower an antigen
activation threshold for its BCR, 100- to 10,000-fold (61). C3d/Ag
complexes are generated on unprotected body cell ormicrobe sur-
face antigens, to which C3b-thiol ester domain C3d (TED) makes
covalent bonds with Ag-hydroxyl groups. These are captured,
processed, and presented in draining lymph nodes to B cells by
FDCs. CD19 co-receptor also mediates DC retention in germinal
centers and their survival (96). CD19/CD21/BCR complex can be
translocated to B cell lipid rafts, which can interact with other
signaling receptors (97).
CD19 glycoprotein is involved in intrinsic Src-family kinase
signaling, associated with Inositol 1,4,5-trisphosphate 3-kinase
(IP3 3-kinase/IP(3)K), Ca2+ influx, andmitogen activated protein
(MAP) kinase (97, 98). A further BCR co-receptor is Bruton tyro-
sine kinase (Btk), expressed constitutively, and positively modu-
lating BCR signaling. As tested in CD19 – promoter – Btk trans-
genic mice, an over expression of Btk within their B cells via NF-
κB elicited in such animals a SLE-like anti-dsDNA autoimmunity,
showing expansion of specific plasma cells. This phenotype was
due to impairment of antigen specific BCR negative selection (99).
Btk gene deletion, on the other hand, resulted in programed death
1 (PD1) expression, B cell apoptosis, and in hereditary disease
such as X-linked agammaglobulinemia. Normally, Btk may thus
directly maintain a threshold on antigen specific B cell negative
selection, although its expressionmodulation itself may be subject
to other BCR co-regulators. B cell malignancy such as chronic
lymphocytic leukemia (CLL) is associatedwith a dysregulated Btk,
and ameliorated by its inhibitors (99).
CD19-co-receptor is closely associated with CD22, an
inhibitory co-receptor of BCR signaling, a member of Siglec
family (sialic acid-binding Ig-like lectin). On IgMmBCR
ligation and via CD19 Lyn kinase, CD22 is activated through
phosphorylation of its immunoreceptor tyrosine based inhibition
motifs (ITIMs). These activated motifs then recruit inhibitory
tyrosine phosphatases such as SHS-1, SHS-2, and inositol-
phosphatase (SHIP), dephosphorylating their substrates,
including CD19 cytoplasmic domain tyrosine residues, as a
negative feed-back loop (100, 101). CD22 and Siglec-G defect and
polymorphism in acetylesterase are associated with susceptibility
to autoimmune disease (102, 103).
C1q, which is highly expressed on B cells, may negatively
influence BCR signaling, and promote their tolerogenic capac-
ity. It may be part of the negative C1q/gC1qR pathway, which
suppresses CD4+ T cell activation and proliferation (54). Earlier
studies with B cell lines, such Raji, Daudi, U937, and Molt4,
demonstrated aC1q-induced anti-proliferative response (55). C1q
promoted human peripheral blood and tonsillar B cell differenti-
ation, stimulated with S. aureus Cowan (SAC), but did not affect
their proliferation. C1q specifically induced IgG production over
that of IgM, via its collagen domain, bound to B cell surface (20).
Apparently both C1q receptors may be engaged in B cells with
separate functions, depending onB cell stage and stimulation (20).
In a comparative study on C1q and on HCV core protein
effects, via gC1qR ligation, C1q likewise did not enhance normal
human CD20+ B cell proliferation, stimulated by phytohaemag-
glutinin (PHA). However, C1q, likeHCV core protein, augmented
CD69 expression, which is an activation marker and an immune
suppressor (81, 83). By contrast, HCV core protein augmented
B cell proliferation, co-stimulatory molecule expression, down-
regulated suppressor of cytokine signaling-1 (SOCS-1), and up-
regulated STAT-1 activation-phosphorylation. In T cell, it had
opposite effects. These responses were gC1qR dependent, and
associated with TIM-3 function. Such cell signaling dysregulation
is thought to sustain the viral disease chronicity and autoimmu-
nity (83, 85). C1q/gC1qR effects on T and B cells may be compat-
ible with C1q being a tolerogenic protein against autoimmunity
as in SLE (63). Its stimulatory effect on B cell CD69 expression
may be relevant. CD69 is a type 2 lectin receptor, expressed
on all bone marrow derived leukocytes. Its co-expression on a
Foxp3 Treg subset facilitates its tolerogenic property. Potentially,
it may also augment such effects of CD11b/CD22 receptors in
B cell tolerance (104). CD69 is a negative regulator of leukocyte
migration-egress of lymphocytes from lymphoid organs, inhibit-
ing sphingosine 1-phosphate receptor-1 (S1P1) (81, 105). gC1qR
is a multi-ligand binding adaptor protein to various cell receptors
(45). In adipocytes, it serves as a positive co-receptor to insulin
receptor tyrosine kinase in insulin signaling (106). In B cells, it
might be a tolerogenic co-receptor.
Autoantibodies Against C1q
Autoantibodies against C1q collagen region have been strongly
correlated with lupus nephritis, suggesting their pathogenicity
(107). In a mouse model, it was revealed that anti-C1q autoanti-
bodies were glomeruli damaging only in conjunction with com-
plement fixing ICs with anti-nuclear protein and dsDNA anti-
bodies deposits (108). Apparently, C1q also exhibits hidden epi-
topes when bound to various cell debris (107, 109). Anti-gC1q
autoantibodies were detected in several SLE nephritis patients,
which inhibited C1q binding to IgG and C-reactive protein. It
has been suggested that such autoantibodies may represent an
acquired C1q deficiency (110, 111). Secondary C1q deficiency
is much more common in SLE and other diseases with variable
frequency. However, only 20–50% of SLE patients have anti-
C1q autoantibodies. Some disease free people also have anti-C1q
autoantibodies, suggesting a need for an injury as a trigger. To
sustain the disease, however, anti-nuclear antibodies and ICs, also
mediated largely by C1q, are a hallmark for SLE (107).
Thus, C1q may distinctly contribute to apoptotic cell phago-
cytic clearance as well as tolerance maintenance to such natural
self-antigens, effects which may be cooperative. C1q may employ
in these tasks its cC1qR as well as its gC1qR in negative anti-
inflammatory pathway of T and B cells. Both C1q receptor expres-
sion is required in DC differentiation and consequently in antigen
presentation to T and B cells. On debris clearance, DCs may
assume a tolerogenic, anergic state. Antigen stimulated T cells
and B cells may respond similarly to C1q negative regulation.
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Autoimmune disease, such as SLE, is heterogeneous and complex.
Its susceptibilitymay be increased not only by C1q defects but also
by malfunction of other genes such as of BCR co-receptor Btk,
CD22, TIM-3, and Tregs in BCR signaling. There is clearly a gene
redundancy in apoptotic cell clearance mechanism. Thus, there
is a good argument to explore the negative C1q/gC1qR pathway
further in autoimmune disease.
Role of C1q in Pregnancy
Activation and Regulation of Complement in
Human Pregnancy
Healthy normal pregnancy is associated with systemic activa-
tion of complement system (112–114). Placenta with the semi-
allogenic fetal tissue is a potential target for complement-mediated
immune attack (115, 116). During normal pregnancy, comple-
ment system is found activated by the presence of natural IgG
in the normal placenta. This needs to be well regulated to con-
trol alloreactivity and placental inflammation (117). Complement
products are found deposited on the placental tissues (118–121).
Following decidual invasion of the fetal tissues, the fetus gets
exposed to the complement system in the maternal blood at
the intervillous space (122). In addition, extravillous trophoblasts
(EVT), known as endovascular trophoblasts, migrate down the
luminal walls of the spiral arteries and eventually enter the decidua
and cause deep vascular changes in the spiral arteries producing
apoptotic debri that favors complement activation with limited
placental damage related to vascular remodeling process (123,
124). However, excessive or uncontrolled activation of the com-
plement system can provoke adverse outcomes damaging the fetal
tissues. Thus, for successful pregnancy, complement activation
requires proper regulation.
During normal pregnancy, fetus specific antibodies such as
anti-HLA and anti-trophoblast antibodies inmaternal serumbind
C1q and activation of the classical pathway can have adverse preg-
nancy outcomes (125, 126). A number of complement regulators
including factor H (117), decay-accelerating factor (DAF, CD55)
(127), membrane co-factor protein (MCP, CD46), and CD59 (128,
129) are expressed locally on the surface of the cytotrophoblasts,
syncytiotrophoblasts coating the villi, and EVT (130, 131). Thus,
complement system at the feto-maternal interface defends the
mother and the fetus against the invading pathogens; protects
the fetus from the maternal immune system and maintains fetal
tolerance (Figure 2).
Distribution of C1q in the Female Reproductive
Tract
The levels of complement components gradually rise with ges-
tation. C3, C4, C5, factor B, factor H, and factor I have been
detected in amniotic fluid, umbilical cord blood (132–134),
utero-placental spiral arteries (135), and placental tissue (136).
Recently, deposition of early (C1q and C4) and late (C5, C6,
C9) complement components has been reported in the pla-
centa (123). Most notably, early components are detected in the
stroma of the villi around fetal vessels, while late complement
components are detected on the trophoblast membranes (118).
Spiral arteries in the first trimester decidua show both early
and late complement component deposits. C1q is produced by
the trophoblasts and decidual endothelial cells (DECs) (118),
human decidual stroma, and synthesized invasive EVT (118,
137). Recently, non-immune decidual cells such as invasive tro-
phoblasts and stromal cells have been shown as a major source
of C1q at the feto-maternal interface using first trimester human
placenta (138).
Role of C1q at the Fetal–Maternal Interface
During Pregnancy
C1q is considered to have a key role in trophoblast invasion,
spiral artery remodeling, and normal placentation (139). C1q is
produced by DECs that connect the endovascular trophoblasts
and the endothelial cells required for normal placentation such
as trophoblast invasion into the decidua and vascular remodeling
during pregnancy (118, 137, 140). In addition, it enhances tro-
phoblast adhesion and migration by the activation of MAP kinase
pathway via gC1qR/P33 integrin (137). Recently, transcriptional
factor, PU.1 has been shown to be associated with the decidual
C1q expression in trophoblasts and stromal cells. PU.1 transcrip-
tional factor is associated with the development of hematopoietic
myeloid lineage immune cells (141). Thus, the presence of PU.1
and C1q at the feto-maternal interface is likely to be involved in
the regulation of trophoblast and stromal cell linage differentia-
tion during early stages of pregnancy such as implantation and
placentation (142).
Association of C1q with Disorders and
Complications of Pregnancy
Excessive complement activation has been associatedwith adverse
pregnancy outcomes such as miscarriages, preterm delivery, and
preeclampsia. During pregnancy, EVT invades the decidua until
it reaches the inner third of the myometrium. The extent of
trophoblast invasion needs to be regulated. Inadequate tapering
of maternal arteries and improper trophoblast invasion has been
associated with preclampsia. It is a common disorder character-
ized by abnormal placentation. C1q /  mice show key features
of preeclampsia, such as hypertension, albuminuria, endothe-
liosis, decreased placental vascular endothelial growth factor
(VEGF), increased soluble VEGF receptor 1 (sFlt-1), increased
oxidative stress, decreased blood flow, increased fetal death,
diminished litter size, abnormal invasion of trophoblasts, and
increased levels of STAT-8 (inhibitor of trophoblast migration)
(139). Furthermore, C1q /  mice are unable to clear apop-
totic trophoblasts whose accumulation can result in abnormal
placentation (92). Differences in the C1q deposition in pla-
cental samples between early and late-onset of preeclampsia
groups can act as a good biomarker for preeclampsia (143). It
appears that C1q produced by trophoblasts are responsible for
impaired trophoblast migration and abnormal placentation. It
is also likely that the trophoblast C1q is required for the cross-
talk between the EVT and DEC to promote trophoblast migra-
tion, vascular remodeling, and normal placentation process (140)
(Figure 3).
Normal pregnancies are characterized by increased anti-C1q
autoantibodies in the serumwhen compared to complicated preg-
nancies. Ectopic pregnancies have the lowest levels of anti-C1q
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FIGURE 2 | Complement activation at the feto-maternal interface
during pregnancy. (A) During normal pregnancy, maternal endometrium
transforms into feto-maternal interface (decidua) and surrounds the
implanted embryo offering nutrition and protection against the maternal
immune system. With advancing gestational age, decidua undergoes
extensive tissue remodeling (trophoblast invasion and spiral artery
formation) that results in apoptotic debris formation. The apoptotic debris
and placental IgG activate classical pathway via C1q deposited at the
feto-maternal interface. By eliminating the immune complexes and
apoptotic cells, complement system protects the mother and fetus.
Complement regulatory proteins found on human placental tissues such as
Factor H, DAF, MCP, CD46, and CD59 prevent excessive complement
activation. (B) In the absence of regulatory proteins (DAF, MCP, CD46,
CD59), excessive complement activation results in improper placentation,
characterized by increased ROS, inflammatory cytokines, angiogenic
proteins (accumulation of apoptotic cells), improper vascularization, and
spiral artery remodeling contributing to development of
pathological/complicated pregnancies.
antibodies with increased IL-15. Thus, IL-15 and anti-C1q anti-
bodies are good serum biomarkers for missed abortions (144).
Clinically, spontaneous miscarriage, still birth, and fetal resorp-
tion have been detected in mothers exposed to polychlorinated
biphenyls (PCBs) (145). In patients with spontaneous abortion,
PCBs content is associated with increased expression of gC1qR,
and reduced percentage of apoptotic cells. Thus, gC1qR may be
relevant for PCBs-mediated trophoblast cell apoptosis (146). Vil-
litis of unknown etiology (VUE), characterized by inflammation
in the chorionic villi, has been associated with miscarriage (147).
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FIGURE 3 | Significance of C1q in normal and adverse pregnancy.
Absence of C1q results in abnormal invasion of fetal trophoblast into the
decidua. C1q deficiency increases oxidative stress and accumulation of
apoptotic trophoblasts. This has an adverse effect on placenta inhibiting
the generation of placental vascular endothelial growth factor (VEGF) and
blood flow, resulting in implantation failure and pregnancy complications
such as recurrent pregnancy loss, miscarriage, abortion, and
preeclampsia.
In a study using placental samples with and without VUE, the
distribution and amount of C1q, C3d, IgG, and IgM in the
chorionic villi were examined. The only difference observed
between two groups was the abnormal distribution of C1q
in the stromal villi (148), suggesting involvement of C1q in
villitis.
Several pathogens including Trypanosoma cruzi,
cytomegalovirus, Listeria monocytogenes, and Neisseria
gonorrhea can infect the decidua, and then spread to placenta
and chorioamniotic membrane. When left untreated, the
chorioamnionitis can lead to preterm birth, intrauterine growth
retardation, still birth, and other complications of pregnancy
(149). T. cruzi protozoan infection that spreads to humans by
blood sucking bug Triatominae (150) can be transplacental,
being passed from the mother to the fetus (151). When the
mother is infected, the T. cruzi calreticulin (TcCRT; 45 kDa),
migrates from the endoplasmic reticulum to the external surface
of the parasite and binds to the maternal C1q (152). TcCRT
bound maternal C1q recognizes/binds to CRT in the placenta.
Thus, TcCRT bound maternal C1q acts as a molecular bridge
to spread T. cruzi infection from the mother to the placenta.
TcCRT, a potent virulence factor, enhances infectivity in the
host by preventing the activation of the classical pathway and
angiogenesis (153, 154). By enhancing the cross-talk between
the CRT found on the surface of the parasite and its receptor on
human placenta, maternal C1q is thought to play crucial role in
spreading T. cruzi infection (155). During pregnancy, there is a
possibility of increased disseminated gonococcal infection. Fetus
remains at an increased risk due to neonatal sepsis, arthritis and
systemic illness. Under in vitro conditions, C1q incubated with
N. gonorrhoeae increases the gonococcal cell infection instead of
clearing the gonococcal bacteremia (156). DECs have previously
been shown to synthesize C1q during pregnancy (118). DECs,
as opposed to endothelial cells isolated from adult skin, display
decreased levels of TLR-4, MD2, and MyD88. This raises the
possibility that C1q at the feto-maternal interface may contribute
to immunoregulation of excessive inflammation caused by
infection during pregnancy (157).
Potential Therapeutic Agents to Prevent
C1q-Associated Pregnancy Disorders
Heparin, a well-known anti-coagulant, has been shown to reduce
pregnancy complications in women with anti-phospholipid
(aPLs) antibodies (158, 159). It prevents apoptosis of human
trophoblasts (160), enhances placental proliferation (161), and
reduces EVT invasion (162). Heparin binds to the C1q colla-
gen region following gC1q binding to ICs, thereby reducing the
classical pathway activation (163, 164).
Animal studies have shown use of statins as a promising thera-
peutic strategy in preventing the onset of preeclampsia. Pravas-
tatin treatment in C1q /  mice prevents the key features of
preeclampsia by lowering blood pressure, and improving vascular
reactivity, endothelial function, and normal placental VEGF. The
study highlights the effectiveness of provastins in order to improve
placentation and pregnancy outcomes (139).
Role of C1q in the Pathophysiology of the
Central Nervous System
Many components of immune system including complement
proteins are locally produced in the CNS in order to maintain
homeostasis. Similar to its role in the peripheral system, C1q
is associated with protection of the CNS against infections such
as bacterial meningitis. Low-level complement activation is also
considered to be beneficial in the removal of toxic or aggregated
proteins. However, sustained or chronic activation can be detri-
mental to the CNS due to microglial activation and production of
pro-inflammatory cytokines. Therefore, neuroinflammation plays
a role in the maintenance of homeostasis or neuroprotection as
well as neurotoxicity, depending upon the level of complement
activation (165–167). Apart from having an important role in
CNS infections, traumatic brain injury, neurodegenerative dis-
eases, and other neurological and psychiatric conditions (Table 2;
Figure 4), a novel role for C1q has been established in the
pathogenesis of prion diseases, development of CNS and synaptic
pruning.
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TABLE 2 | Role of C1q in CNS diseases.
CNS disease Role of C1q Reference





C1q binds to β-amyloid via B chain of gC1q
region and modulates phagocytosis by
microglia
(2, 168)
Absence of C1q causes less neuropathology
in AD mouse models
(169)
Co-localization of C1q with neurons is
observed in pre-clinical stage of AD
(170)
Increase in reactive oxygen species in neurons
incubated with C1q leading to neurotoxicity
(171)
In the presence of C1q, the neurotoxic effects




Neuromelanin opsonized by C1q and




Co-localization of C1q with reactive astrocytes
in CNS plaques
(173)
Schizophrenia Increase in serum C1q and increased total




Deficiency of C1q improves recovery following
SCI
(175)
Stroke Presence of C1q in ischemic lesions (176)





Increased C1q co-localization in striatum (178)
Microglia, astrocytes, and neurons are known to be good
sources of complement proteins especially under stress, injury,
ischemia, or infection. Microglia are the specialized macrophages
in the CNS that constantly survey their surroundings. Upon being
activated by environmental or external stimuli, microglia retract
their ramifications and appear amoeboid. Production of C1q by
microglia is at low level in the resting phase, which increases upon
activation, leading to production of pro-inflammatory cytokines
that can cause neuronal cell death (179). C1q binds to apop-
totic cells and neuronal blebs thereby enhancing phagocytosis
by microglia. Farber et al. (180) found that C1q stimulated
microglial synthesis of TNF-α and IL-6, which is considered
to disrupt blood–brain barrier. Moreover, C1q released by acti-
vated microglia maintained and balanced the level of activa-
tion of microglia in an auto- or paracrine manner. Interestingly,
microglia stimulated with C1q in vitro were found to decrease
LPS-induced production of TNF-α and IL-6 (181). Astrocytes
have been shown to produce C1q in response to cerebral fungal
infection (182). Astrogliosis refers to change in morphology and
hypertrophy of astrocytes, which leads to scar formation. This
occurs in response to CNS insult and is associated with C1q and
cytokine secretion. Furthermore, co-localization of C1qwith reac-
tive astrocytes is a significant feature of CNS plaques seen in mul-
tiple sclerosis patients (173). Neurons also produce C1q in vitro
(183). For example, hippocampal cells secrete C1q in response
to β-amyloid (184). Presence of C1q protects neurons against
β-amyloid and serum amyloid P-induced neurotoxicity (48).
C1q-mediated neuroprotection involves up-regulation of genes
associated with cholesterol and lipid distribution/metabolism
such as cholesterol-25-hydroxylase and insulin induced gene 2.
Addition ofC1q leads to decreased levels of cholesterol in neurons,
which is known to be a factor that causes outgrowth of neurites.
C1q also directly affects nerve growth factor (NGF) by upregulat-
ing its transcription factors and downregulation ofmicroRNA that
target NGF (185). Thus, C1q (and the complement system) has
a dual role: beneficial as well as detrimental to the CNS offering
opportunities for therapeutic intervention in neuroinflammatory
and neurodegenerative diseases.
Prion Diseases
Prion diseases or transmissible spongiform encephalopathies are
a group of neurodegenerative diseases that are infective and are
known to occur in humans, cattle, deer, and other livestock
such as sheep and goat. Some of the diseases that affect humans
include Creutzfeldt–Jakob disease (CJD), fatal familial insomnia,
and kuru; while those involving animals include bovine spongi-
form encephalopathy and scrapie. Prion proteins are normally
present in human body, although the fibrillar form of this prion
protein (PrPSc: scrapie-associated prion protein) are cytotoxic and
form protease resistant fibrils and oligomers. PrPSc accumulates
in neurodegenerative disease plaques. Histopathological features
observed in prion disease affected brains include spongiform
changes, gliosis, loss of neurons, accumulation of amyloid plaques,
and synaptic degeneration in hippocampus (186–188).
C1q is involved in uptake, propagation, and transmission of
PrPSc from the gut to the brain. With the exception of direct
brain exposure due to neurosurgery, the mode of transmission
for prions is through oral or parenteral route. C1q /  or C3 / 
mice have been found to have significantly delayed onset of disease
after peripheral exposure to PrPSc (49). C1q plays a role in the
initial uptake of PrPSc by conventional DC that express C1q
receptor calreticulin (50). Absence of C1q has been found to sig-
nificantly reduce the capture of prions by DC (189). Additionally,
follicular DC is also considered to be a good source of endoge-
nous monomeric prion protein. C1q interacts with PrPSc in an
antibody-independent manner, which is considered to proliferate
on the surface of follicular DC (190). Inactivation of follicular DC
was found to delay neuroinvasion by PrPSc (191). In vitro studies
using human microglial cells have also shown that the presence
of C1q along with PrP causes an increase in fibril formation
of PrP. This leads to an increased activation of microglial cells
causing secretion of pro-inflammatory IL-6 and TNF-α (192).
C1q has been found to enhance formation of PrP oligomers and
form complexes with these PrP oligomers via its gC1q domain.
This complex has the ability to activate classical pathway, and
this is considered to prevent neuronal cell death caused by these
oligomers of PrP (51). However, this interaction is considered
to prevent the elimination of prion seed, thereby increasing its
aggregation. Thus, C1q is involved in initial pathogenesis of prion
disease by enhancing uptake of prions in the peripheral system,
propagating into CNS, forming complexes with PrP oligomers,
and increasing fibril formation.
Synaptic Pruning
C1q (and the complement system) has been shown to play a vital
role in synapse elimination during developmental stage of CNS
Frontiers in Immunology | www.frontiersin.org June 2015 | Volume 6 | Article 31710
Kouser et al. Emerging functions of C1q
FIGURE 4 | Various diseases of central nervous system and the
involvement of C1q. various functions of C1q in the central nervous
system and the associated diseases are illustrated. Increased levels of
C1q have been found in Huntington disease and schizophrenia. In
Huntington disease, striatal volume is decreased in mouse models;
however, cell number does not differ. Prion disease is a result of undue
loss of neurons and misfolded prion protein, PrPSc, deposition. Early
synaptic failure and neuronal loss affect behavioral symptoms, indicating
the early onset of disease. C1q deficiency reduces the capture of prions
by DCs, as it is only involved in the primary phase of the disease,
transmitting prions to the CNS. C1q production is triggered in the CNS by
astrocytes in response to cerebral fungal infection. The role C1q plays in
Parkinson’s disease includes the opsonization of neuromelanin and
phagocytosis by microglia cells. Complement pathway up-regulation in
brain regions can be observed in AD, which may be due to amyloid β
peptides binding within collagen-like domain of C1q, thus activating
classical pathway. In addition, fibrillar amyloid β interaction with C1q via
activates the classical pathway. Microglia cells, which express C1q in the
substantia nigra pars compacta of Parkinson disease, phagocytose and
clear debris of degenerating neurons.
as well as in synaptic pruning to increase efficiency of neuronal
transmission. During developmental stage, a redundant growth
of neural network occurs which also leads to excessive synaptic
formations. This needs to be kept in check in order to maintain
plasticity and ensure proper functioning of the CNS. Complement
proteins, includingC1q, have been localized at the sites of synaptic
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elimination in the mouse reticulogeniculate system, which is a
model for studying synapse elimination during developmental
stage (47). C1q is involved in synapse elimination during the
developmental stage of CNSwhere postnatal neurons express C1q
in response to an astrocyte-mediated signal and then co-localizes
with developing synapses. C1q /  mice show failure of synapse
elimination (47). Thus, role of C1q is considered to be akin to that
in the peripheral system wherein C1q tags apoptotic cells. In the
CNS, C1q is considered to tag immature or unwanted synapses
leading to their elimination by microglia.
An important element of glaucoma includes death of reti-
nal ganglionic cells (RGCs). In mouse retina, C1q is expressed
only during the developmental phase. Interestingly, in glaucoma
mouse model, C1q re-localizes to synapses in adult inner plex-
iform layer of the retina. This mechanism could be an impor-
tant early event in glaucoma leading to C1q-mediated tagging of
synapses, which, in turn, causes synapse loss and death of RGC.
Furthermore,C1qA andC1qB chain gene expression was found to
be markedly elevated (up to 25-fold) in mouse retinas with mod-
erate glaucoma (47).More recently, TGF-β, secreted by astrocytes,
has been shown to induce production of C1q by purified RGC
(193). Disruption in cytokine signaling pathway of TGF-β leads
to inhibition of synaptic pruning in vivo that is dependent on C1q
and microglia. Furthermore, C1q has been also found to regulate
microglia-mediated synaptic pruning in the thalamus (193).
Failure of synaptic pruning is an essential aspect of epilepto-
genesis. C1q /  mice show aberrant synaptic connectivity and
spontaneous epileptiform activity is evident (194). This is likely
due to the presence of excessive excitatory synapses. This failure
of synaptic pruning also contributes to a significant increase in
dendritic length, branching, and density of dendritic spines in
C1q /  mice (195). In a rat model of temporal lobe epilepsy, an
increase in C1q production by glial cell and neurons was observed
in hippocampus following status epilepticus (196). Role of C1q
in epilepsy is currently ambiguous. Due to an increased activa-
tion of complement, neuroinflammation can reduce threshold
for seizures. On the flipside, its absence leads to spontaneous
epileptiform activity due to deficient synaptic C1q function.
An increase in C1q level (up to 300-fold) has been observed
in aging brain, especially in pyriform cortex, substantia nigra,
and hippocampus (197). C1q immunoreactivity was detected in
microglia throughout the early postnatal brain. Interestingly, C1q
also co-localized with inhibitory (GABAergic) neurons in the
hippocampal dentate gyrus. C1q was also abundant in close vicin-
ity of synapses. Furthermore, the increase in C1q level in aging
brain also correlated with cognitive decline. Indeed, synaptopa-
thy or synaptic dysfunction is considered to be the one of the
earliest feature of neurodegenerative diseases such as Alzheimer’s
disease, Parkinson’s disease, Huntington’s disease, and Prion dis-
eases (198, 199).
Induction of Apoptosis in Cancer Cells
by C1q
Human prostate cancer cells DU145 express WOX-1, which is
known to be a tumor suppressor and pro-apoptotic protein.When
DU145 cells cultured overnight in the presence of heat-inactivated
serum (10%) followed by starvation for 1 h without serum were
treated with exogenous C1q, it induced rapid accumulation of
nucleic Tyr33-phosphorylated WOX-1 (p-WOX1) in comparison
with the C1q-depleted serum treated cells where p-WOX1 was
mainly localized in the cytoplasm (38). The C1q-treated DU145
cells adhered to the cover glass surface and a significant increase
in the formation of clustered microvilli in between the cells was
observed. Subsequently, the cell membrane shrunk, membrane
blebbed, and eventually the cells underwent apoptosis. The inter-
nucleosomal DNA fragmentation analysis showed the cleaved
DNA ladders, which further established the C1q/WOX1-induced
apoptosis in the DU145 cells.
The activation of WOX1 by C1q was further determined by
culturing the EGFP–WOX1 and EGFP alone transfected DU145
cells overnight (in 10% heat-inactivated fetal bovine serum) fol-
lowed by C1q treatment for 24 h. The C1q treatment resulted in
activation of WOX1-induced apoptosis and growth suppression
of the DU145 cells in the EGFP–WOX1 transfected cells whereas
C1q did not induce apoptosis in the DU145 cells overexpressing
EGFP vector only. These findings also suggest that WOX1 was
a downstream effector of C1q-mediated apoptosis without the
involvement of complement activation since the serum was heat
inactivated.
Out of the two domains, N-terminal WW and C-terminal
short chain alcohol dehydrogenase/reductase (SDR) of WOX1,
the WW domain is believed to be involved in the C1q-induced
activation of WOX1. This was shown by transfecting the DU145
cells with a dominant negative-WOX (dn-WOX1), which was
designed with alterations in the N-terminal WW and is known
to block the apoptotic function of p53 and prevent phospho-
rylation of endogenous WOX1 at Tyr33. The transfected cells
resisted C1q-induced apoptosis when transiently overexpressed
with dn-WOX1 (EGFP tag) whereas non-transfected cells under-
went apoptosis. Furthermore, co-transfection of DU145 cells with
N-terminal WW domain of WOX1 (WOX1ww) and dn-WOX1
showed a decrease in the C1q-induced apoptosis. These obser-
vations suggest that N-terminal WW domain of WOX1 and the
Tyr33 phosphorylation in WOX1 play an important role in C1q-
induced apoptosis.
To determine the role of p53 and WOX1 in C1q-regulated cell
death, DU154 cells were transiently overexpressed with both p53
andWOX1. TheDNA fragmentation significantly increased in the
combination compared to p53 or WOX-1 alone expressing cells,
suggesting that tumor suppressor p53 physically interacts with
WOX1 to induce apoptosis. However, alterations of humanWOX
gene occur most frequently in the prostate. Therefore, prostate
tissues were examined for the expression of C1q. The immunoflu-
orescence comparison of the age-matched prostate tissue with the
benign prostatic hyperplasia (BPH) and prostate cancer showed
that C1q was significantly down-regulated in the later tissues.
These findings raised a question whether down regulation of C1q
in vivo may reduce the activation of tumor suppressors, which
would subsequently result in better survival of the prostate cancer
cells. Therefore, when DU145 cells were cultured overnight under
serum free conditions, in the presence of 1%normal human serum
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or 1% human serum deficient in C1q, C6, C7, C8, or C9, it was
noted that C1q and C6 were essential for the expression of WOX2
(isoform of WOX1) and p-ERK and remainder conditions did
not support the expression of these proteins. These observations
were further confirmed by immunofluorescence microscopy and
western blot that showed the downregulation of p-WOX1 under
C1q or C6 free conditions, and hence no apoptosis was seen.
Similarly, p53 nuclear accumulation was reduced in the C1q or
C6 free conditions whereas C9 free conditions promoted the
accumulation of p53 in the nuclei suggesting that C9 restricts
the p53 activation. C1q and C6 were also shown to block JNK1
activation, which is known to block the apoptotic function of
WOX1 in vitro.
In addition, hyaluronic acid was shown to activate STAT3 in
the DU145 cells when cultured in the C1q deficient conditions,
which causes metastasis by up regulating the STAT3 phosphory-
lation, suppression of p53, and WOX1 activation. The induction
of apoptosis by C1q in the cells overexpressing WOX1 such as
breast cancer cells (MCF7), neuroblastoma SH-SY5Y, and SK-
N-SH cells was also established. It appears that C1q plays a
key role in the activation of tumor suppressor WOX1, which is
required for blocking the cancer cell proliferation. C1q did not
enhance the p53-mediated apoptosis; however, p53 and WOX1
balanced binding interaction results in their synergistic effect
in inducing apoptosis in response to the C1q treatment. The
downregulation of C1q enhances prostate hyperplasia due to
a failure of WOX1 activation failure and increased activation
of STAT3. It is worth pointing out here that the pro-apoptotic
effect of C1q observed on human prostate cancer cells is an
exceptional and novel phenomenon reported. C1q has often been
detected at tumor site where its expression is associated with
tumor progression.
Role of C1q in Aging
Serum C1q concentration and expression increases with aging,
which causes impaired regeneration capacity of various tissues by
activating canonical Wnt signaling pathway (33). Wnt signaling is
known to play a key role in tissue development including stem cell
self-renewal, degenerative diseases, and carcinogenesis. During
canonical Wnt signaling pathway, Wnt binds to the two types
of receptors, Frizzled (Fz) family of serpentine proteins and the
single-transmembrane protein low-density lipoprotein receptor-
related protein 5/6 (LRP5/6), which causes the disruption of the
β-catenin destruction complex by recruiting the Axin component
of destruction complex to the cytoplasmic tail of the Wnt co-
receptor LRP. The β-catenin destruction complex includes pro-
teins: Axin, adenomatosis poluposis coli (APC), protein phos-
phatase 2A (PP2A), glycogen synthase kinase 3 (GSK3), and
casein kinase 1 α (CK1α). Therefore, canonical Wnt signaling
pathway causes the β-catenin cytosolic accumulation and translo-
cation into the nucleus to act as a transcriptional co-activator
of the T cell factor/lymphoid enhancer factor (TCF/LEF) family
(Figure 5).
C1q has been shown to activate the canonical Wnt signaling
by binding to the Fz receptor and stimulating C1s-dependent
cleavage of the ectodomain of LRP6. This C1q-induced activation
of Wnt signaling subsequently stabilized the cytosolic β-catenin
and increased the expression of Axin 2, a known target gene
of canonical Wnt signaling. A heterologous competition assay
demonstrated that C1q competed with Wnt for binding to
Frizzled-8 (Fz8) cysteine-rich domain (CRD) with comparable
affinity, however, 200-fold higher EC50 of C1q was observed than
Wnt3A. This observation was further supported when an increase
in the levels of Axin 2 mRNA was observed in various tissues of
the 2 years old wild-type mice compared with 2months old and
C1q /  mice, suggesting the relevance of C1q-induced canonical
Wnt signaling activation in the aged animals. Similar trend was
observed in the isolated satellite cells and fibroblasts from the
muscles of young and old mice treated with C1q suggesting a
decreased regenerative capacity of skeletal muscles. In addition,
with increasing age, an increased amount of the cleaved product
of LRP6 was detected in the serum of wild-type mice but not in
C1q /  mice. These observations strongly suggest the physiolog-
ical relevance of C1q-induced activation of Wnt signaling. How-
ever, the extent of this activation is dependent on various factors
such as concentration of C1q, target cell exposure, expression level
of Fz receptors, LRP5/6 co-receptors, C1r, C1s, and C1 inhibitor
in the target cells. In conclusion, the serum C1q concentration
increases with aging, which induces canonicalWnt signaling path-
way and thereby C1q mediates impaired regenerative capacity of
skeletal muscle in aged animals.
Role of C1q in Wound Healing
C1q deposited on the endothelial cells of wound healing skin play
a crucial role in promoting angiogenesis by inducing permeability,
increased rate of proliferation and tube formation (39, 118). The
presence of C1q in the endothelium and stroma of the granu-
lated tissue and its absence in the intact skin was confirmed by
immunmohistochemical analysis. C1q transcripts could be seen
in stromal cells and vascular endothelium of the lesions, whereas
it was undetectable in the cells of intact skin. C1q (10µg/ml) has
been shown to promote permeability, proliferation, andmigration
of endothelial cells. This effect of C1q appears to be mediated via
its gC1q domain.
When C1q was tested using in vitro tube formation assay that
involves growing endothelial cells and staining them for actin
to visualize tube formation, C1q, like VEGF, induced marked
changes in the cell pattern, with the formation of tubules assem-
bled by elongation and joining of endothelial cells (200, 201). An
ex vivomodel of rat aortic ring assay was used to analyze the effect
of C1q on vessel sprouting from aortic rings. The microvessels
formation induced by C1q was visible after 6 days (more apparent
after 9 days).
In a mouse model of wound healing using C1q /  mice, the
animals were sacrificed after 14 days post-surgery and skin sam-
ples were collected to analyze for the presence of blood vessels.
A limited number of small vessels were observed in the wound
healing of the C1q /  mice in comparison to the normal angio-
genesis observed in wild-type control. Local application of C1q to
the wound of C1q /  restored vessel formation to the level found
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FIGURE 5 | Serum C1 competes with Wnt for Fz receptor binding,
resulting in Wnt canonical pathway activation. Wnt binds to Fz
receptor and LRP5/6 which causes β-catenin destruction complex (APC,
PP2A, GSK3, and CK1α) by recruiting the Axin component of destruction
complex to the cytoplasmic tail of the Wnt co-receptor LRP. This results
in stabilization and accumulation of β-catenin in the cytoplasm, which
eventually gets translocated into the nucleus to act as a transcriptional
co-activator of the TCF/LEF family and the Wnt canonical pathway is
activated, which has been shown to induce aging. C1q concentration in
the serum increases with age. C1q competes with 200-fold higher
binding affinity with Wnt for Fz receptor and stimulates C1s-dependent
cleavage of the ectodomain of LRP6. The C1q binding to Fz receptor
also blocks the β-catenin destruction complex (APC, PP2A, GSK3, and
CK1α) and results in stabilization of β-catenin in the cytoplasm, which is
then translocated into the nucleus. Subsequently, canonical Wnt
signaling is activated.
in WT mice (39). It appears that this angiogenic property of C1q
is complement-independent.
Perspectives
C1q plays an important role in the clearance of pathogens. C1q
also binds to Gram-positive (S. pyogenes) and Gram-negative
(E. coli) (Table 1) and facilitates clearance of bacterial cells
(34). However, it can also be used as an escape mechanism by
pneumococci, which enhances adherence and invasion in both
epithelial and endothelial cells (Table 1). Although the bind-
ing to the pathogen is via surface-exposed protein(s) and the
gC1q domain, the adherence and invasion is facilitated by the
interaction of C1q collagen region with the host cell-surface
receptor, implying that C1q acts as a link between the host
and pneumococci (34). Pneumococcal endopeptidase O (PepO)
binds strongly to C1q causing activation of classical pathway and
consuming the complement components, which allows escape
mechanism for Gram-positive species Streptococcus pneumoniae.
PepO also binds to the C4BP, an inhibitor of the classical path-
way (37).
C1q has long been considered a prototypical innate immune
molecule with a range of diverse ligands and functions. C1q and
its pathophysiological importance can never be over-estimated.
C1q involvement in apoptotic cell clearance and its deficiency
linked to the development of lupus have been some of the path
breaking observations. Its neuroprotective role in clearing protein
aggregates in the CNS and perhaps exaggerating neuroinflamma-
tion is firmly established. The local synthesis of C1q by immune
and non-immune cells and its functions independent of other
complement proteins have put the molecule at the forefront of
the homeostatic machinery. Its interaction with novel receptors
linked with apoptosis induction and aging are exciting areas for
further investigation. The roles of C1q in the CNS pathophysiol-
ogy and development are some of the highlights of complement
research in last decade.
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